GlassScriptPhysician profile
Gary Gibson
NPI 1376520924
$2,605.68
in general payments reported to CMS, 2019-2025
23 companies · $600 in 2025
The $600 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.40 · 2020: $23.31 · 2021: $159 · 2022: $477 · 2023: $576 · 2024: $712 · 2025: $600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,888.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,888.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $722.97 | 2022-2025 | |
| Lilly USA, LLC | $340.80 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $319.47 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $236.51 | 2022-2025 | Evenity, Repatha, Prolia |
| Pfizer INC. | $236.47 | 2019-2025 | |
| Glaxosmithkline, LLC. | $98.85 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $71.22 | 2022-2025 | |
| Exact Sciences Corporation | $68.04 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $66.70 | 2021-2024 | Rybelsus, Wegovy |
| Corcept Therapeutics | $60.86 | 2025 | Korlym |
| Averitas Pharma INC. | $54.83 | 2025 | Qutenza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.31 | 2019-2022 | |
| Shield Therapeutics INC | $41.15 | 2023 | Accrufer |
| Medtronic, INC. | $39.76 | 2022-2025 | Vanta Adaptivestim |
| Novartis Pharmaceuticals Corporation | $34.54 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $28.07 | 2024 | Rexulti |
| Merck Sharp & Dohme LLC | $27.81 | 2023 | Dificid |
| Daiichi Sankyo INC. | $26.53 | 2024 | Injectafer |
| Abbott Laboratories | $19.46 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $18.36 | 2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $16.80 | 2025 | Trintellix |
| Sanofi-Aventis U.S. LLC | $15.01 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Gibson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.